Abstract: Database commands may be asynchronously forwarded between nodes of a database system. A read-only node may receive a request, such as a read request or write request, and determine that the request should be forwarded to a read-only node for performance. A thread that handles the request may forward the request to the read-only node and register a call-back event for a response to the request and be made available to perform other work. When the response from the read-write node is received, the call-back event may be triggered and return a response to the request using the same or different thread.

Abstract: Automatic consistency is implemented for forwarding writes in a database system. A read-only node may support both read and write requests to a database. The read only node may forward write requests to a read-write node. The read-only node may determine whether to include the forwarded requests in a version of the database for a read request automatically according to a consistency specified for a read request.

Abstract: Systems, methods, and computer-readable and executable instructions are provided for managing shared memory. A method for managing shared memory can include statically assigning a first number of locks to the shared memory during compile-time and dynamically assigning a second number of locks to the shared memory during runtime.

Abstract: Systems, methods, and computer-readable and executable instructions are provided for managing shared memory. A method for managing shared memory can include statically assigning a first number of locks to the shared memory during compile-time and dynamically assigning a second number of locks to the shared memory during runtime.

Abstract: The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5?-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.

Abstract: One embodiment disclosed relates to a method of compiling a computer program. A plurality of modules of source code is received, and intermediate representations corresponding to the modules are generated. A set of data from the intermediate representations is extracted to create an inliner summary for each module. Using the inliner summaries and a globally-sorted working-list based order, an inline analysis phase determines which call sites in the modules are to be inlined by substituting code from a called module. The propagation of summaries may be done elaborately, potentially throughout the call-graph. The goodness of call sites may be computed with a view to comparing them and ordering them in a descending order of goodness.

Abstract: The present invention relates to novel propionic acid derivatives. More particularly, the present invention relates to beta-phenyl alpha-oxysubstituted propionic acids of the general formula (I). The present invention also relates to processes for the preparation of compounds of the formula (I) and their use in the preparation of compounds of formula (II).

Abstract: The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Abstract: The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5?-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.

Abstract: There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from —CH2—, —O—, —NH—, and —S—; Y is chosen from —O—, —NH—, and —S—; Z, which may be located in any position of substitution, is hydrogen or halogen; R1 and R2, which may be the same or different, are independently chosen from hydrogen and C1-C8 alkyl, or R1 and R2 together form a carbocyclic ring having from 4 to 6 carbon atoms; R3 is chosen from hydrogen and C1-C8 alkyl; R4, R5, and R6, which may be the same or different, are independently chosen from hydrogen and C1-C8 alkyl; and n is 1 to 6. Various embodiments and variants are provided.

Abstract: The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds.

Abstract: The present invention relates to novel hypolipidemic, antihyperglycemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel ?-aryl-?-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Abstract: The present invention relates to novel isoxazole compounds of formula (I) having (PPAR) agonist activity, pharmaceutical compositions containing such compounds and methods for their use.

Abstract: The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Abstract: One embodiment disclosed relates to a method of compiling a computer program from a plurality of files of source code. An inline analysis determines which call sites in the plurality of files to make inline. An inline transformation performs the inlining within currently opened files. The transformer dynamically determines the order of inlines independent of the analyzer by taking into account the disk input-output pressure during compilation. The resulting inline order minimizes the input and output of files from and to disk respectively by considering the inline affinity between files and maintains the best run-time performance by preserving the dependences between call sites. During the inline transformation, a determination of which files to open and close is made in dependence on an affinity weighting between the files.

Abstract: The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Abstract: The present invention relates to novel hypolipidemic, antiobesity, hypocholesterolemic and antidiabetic compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general formula (I), their stereoisomers, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them where all symbols are as defined in the description.

Abstract: The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5?-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel ?-aryl-?-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

Abstract: Novel ?-aryl-?-oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them. The compounds have hypolipidemic, antihyperglycemic uses.